These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30061885)

  • 21. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
    Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
    Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outer membrane vesicle-wrapped manganese nanoreactor for augmenting cancer metalloimmunotherapy through hypoxia attenuation and immune stimulation.
    Luo S; Yang Y; Chen L; Kannan PR; Yang W; Zhang Y; Zhao R; Liu X; Li Y; Kong X
    Acta Biomater; 2024 Jun; 181():402-414. PubMed ID: 38734282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.
    Wei F; Wang D; Wei J; Tang N; Tang L; Xiong F; Guo C; Zhou M; Li X; Li G; Xiong W; Zhang S; Zeng Z
    Cell Mol Life Sci; 2021 Jan; 78(1):173-193. PubMed ID: 32654036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
    Chouaib S
    Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
    Mudassar F; Shen H; Cook KM; Hau E
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma.
    Yan H; Jiang A; Huang Y; Zhang J; Yang W; Zhang W; Liu T
    Front Immunol; 2023; 14():1265914. PubMed ID: 37876940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response.
    Noman MZ; Messai Y; Carré T; Akalay I; Méron M; Janji B; Hasmim M; Chouaib S
    Crit Rev Immunol; 2011; 31(5):357-77. PubMed ID: 22142164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy.
    Fu Z; Mowday AM; Smaill JB; Hermans IF; Patterson AV
    Cells; 2021 Apr; 10(5):. PubMed ID: 33923305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-Driven Immune Escape in the Tumor Microenvironment.
    Vito A; El-Sayes N; Mossman K
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.
    Liu X; Zhao Y; Wu X; Liu Z; Liu X
    Front Oncol; 2022; 12():931104. PubMed ID: 35924168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The regulation of immune checkpoints by the hypoxic tumor microenvironment.
    Hu M; Li Y; Lu Y; Wang M; Li Y; Wang C; Li Q; Zhao H
    PeerJ; 2021; 9():e11306. PubMed ID: 34012727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
    Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strengthening the Combinational Immunotherapy from Modulating the Tumor Inflammatory Environment via Hypoxia-Responsive Nanogels.
    Luo W; Zeng Y; Song Q; Wang Y; Yuan F; Li Q; Liu Y; Li S; Jannatun N; Zhang G; Li Y
    Adv Healthc Mater; 2024 Mar; 13(8):e2302865. PubMed ID: 38062634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma.
    Chaudhary R; Slebos RJC; Noel LC; Song F; Poole MI; Hoening DS; Hernandez-Prera JC; Conejo-Garcia JR; Guevara-Patino JA; Wang X; Xie M; Tan AC; Chung CH
    Cancer Res Commun; 2023 May; 3(5):896-907. PubMed ID: 37377902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.